We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

244 hedge funds and large institutions have $3.12B invested in Axsome Therapeutics in 2023 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 70 increasing their positions, 88 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more call options, than puts

Call options by funds: $79.2M | Put options by funds: $41.4M

83% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 24

30% more funds holding in top 10

Funds holding in top 10: 10 → 13 (+3)

18% more capital invested

Capital invested by funds: $2.65B → $3.12B (+$473M)

8% more funds holding

Funds holding: 226 → 244 (+18)

2.6% more ownership

Funds ownership: 80.28% → 82.88% (+2.6%)

20% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 88

Holders
244
Holders Change
+18
Holders Change %
+7.96%
% of All Funds
3.56%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.19%
New
44
Increased
70
Reduced
88
Closed
24
Calls
$79.2M
Puts
$41.4M
Net Calls
+$37.9M
Net Calls Change
+$18.3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$62.9M
2
PA
Perceptive Advisors
New York
+$37.2M
3
Millennium Management
Millennium Management
New York
+$27.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$20.4M
5
BlackRock
BlackRock
New York
+$20.4M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$65.3M
2
NIP
Nicholas Investment Partners
California
-$20.9M
3
SCM
Soleus Capital Management
Connecticut
-$16.6M
4
Citadel Advisors
Citadel Advisors
Florida
-$13.8M
5
BI
BVF Inc
California
-$10M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$357M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$294M -$2.16M -32,360 -0.9%
BlackRock
3
BlackRock
New York
$258M +$20.4M +305,256 +10%
FFM
4
Fairmount Funds Management
Pennsylvania
$188M +$1.26M +18,839 +0.8%
BI
5
BVF Inc
California
$158M -$10M -150,000 -7%
Morgan Stanley
6
Morgan Stanley
New York
$98.6M +$62.9M +940,337 +315%
Citadel Advisors
7
Citadel Advisors
Florida
$86.7M -$13.8M -206,539 -16%
PA
8
Perceptive Advisors
New York
$82.6M +$37.2M +556,370 +116%
DTC
9
Deep Track Capital
Connecticut
$79.6M -$9.41M -140,745 -12%
RCM
10
RA Capital Management
Massachusetts
$79.6M – – –
State Street
11
State Street
Massachusetts
$73.6M +$3.78M +56,543 +7%
Millennium Management
12
Millennium Management
New York
$72.4M +$27.2M +406,923 +81%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$70.2M -$65.3M -976,529 -53%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$66.6M +$20.4M +305,264 +57%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$65.5M +$2.93M +43,809 +6%
ACM
16
Alethea Capital Management
Washington
$59.9M -$451K -6,750 -0.9%
Pictet Asset Management
17
Pictet Asset Management
Switzerland
$55.6M +$3.51M +52,503 +8%
BG
18
Bellevue Group
Switzerland
$50.6M +$260K +3,885 +0.6%
JFG
19
Jefferies Financial Group
New York
$44.8M +$678K +10,140 +2%
WP
20
Woodline Partners
California
$44.7M +$7.36M +110,056 +24%
PHS
21
PFM Health Sciences
California
$37.2M -$3.73M -55,783 -11%
APM
22
Avidity Partners Management
Texas
$36.6M +$10.9M +162,600 +55%
BC
23
Boxer Capital
California
$31.8M – – –
HRCM
24
Hood River Capital Management
Florida
$31.3M +$634K +9,477 +2%
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$29.1M +$2.67M +40,000 +12%
1
2 3 4 5

AXSM Hedge Fund Activity: Q4 2023 in Review

244 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2023, worth a combined $3.12B — up 18% from $2.65B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new AXSM positions and 24 closed out — a net gain of 20 holders — while 70 added to existing stakes and 88 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $62.9M. The largest seller was Fidelity Investments, cutting an estimated $65.3M.

  • 244 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2023, up from 226 in Q3 2023.
  • Funds reported $3.12B of Axsome Therapeutics stock for Q4 2023, up 18% quarter-over-quarter.
  • 44 funds opened new Axsome Therapeutics positions in Q4 2023 and 24 closed out, a net change of +20 holders.
  • The largest Axsome Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $62.9M added.
  • The largest Axsome Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $65.3M sold.

Based on aggregated 13F filings for Q4 2023.